In a research study focusing on magic mushrooms in Canada, almost 80% of participants voiced their belief that psilocybin should be available as a medical treatment for patients in distress. Furthermore, about two-thirds of the Canadian participants in the same study agreed that psilocybin should be legally accessible for those in need.
In addition to making the substance more readily available, a significant 84.8 percent of participants believe that the public health system should shoulder the costs of such therapies. A majority of Canadians deem psilocybin as a viable option, particularly for the treatment of end-of-life distress.
[toc]
Key Insights:
- Residents of Québec, Ontario, Alberta, and British Columbia regard psilocybin as a valid medical choice for addressing end-of-life existential distress.
- Magic mushrooms are considered to be safe for treating existential distress.
- Participants in two double-blind trials reported immediate and enduring benefits, with effects lasting six months or even longer.
Understanding Existential Distress
Existential distress, which shares similarities with existential suffering, spiritual distress, and demoralization, emerges when individuals confront their mortality. Patients may experience feelings of helplessness, isolation, anxiety, and a loss of meaning and purpose. This type of distress particularly affects patients with life-threatening illnesses, potentially leading to a desire to expedite death or contemplate suicide.
Typically, individuals dealing with terminal illnesses or significant life alterations are the ones who commonly undergo this kind of distress. It drastically affects their mental well-being and overall quality of life.
Existential therapy seeks to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. It can require numerous sessions and may not be effective for everyone.
The uncertainty surrounding the effectiveness of such therapy is a primary reason many individuals pursue alternative treatments.
Health Canada’s View on Psilocybin as a Treatment Option
Over the past twenty years, initial clinical trials have underscored the potential benefits of psychedelic HTML:
The use of substances in treating intricate mental disorders is gaining traction. Psilocybin, in particular, has been shown to swiftly and enduringly alleviate existential distress in patients nearing the end of life.
In acknowledgment of the potential effectiveness of these suggested hallucinogenic mushrooms, particularly when traditional treatments fall short, Health Canada amended the Special Access Program in 2022. This allows healthcare professionals to request controlled substances for their patients.
Support for Psilocybin Access Among Canadians
A study featured in the Palliative Care Journal assesses societal perspectives on psilocybin-assisted therapy for end-of-life care. The study’s data includes:
| Methodology | Participation from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of whom had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% consider psilocybin-assisted therapy a valid medical option for treating end-of-life existential distress. 63.3% believe psilocybin should be incorporated into medical treatment. 84.8% support the provision of this therapy by the public health system. 44.2% feel healthcare professionals should administer the substance without Health Canada’s oversight. |
These results are consistent with surveys from Canada, England, and Australia. The researchers emphasized that their study is unique as it centers on using psychoactive substances to treat existential distress in end-of-life scenarios.
Reasons for Canadian Support of Psilocybin Use
A growing number of Canadians are embracing the use of psilocybin for treatment, largely due to findings from respected research institutions. Another contributing factor is the perceived safety of psilocybin mushrooms for alleviating existential distress. Subjects across various studies have not reported severe negative health impacts, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients were given a high dose of psilocybin and a low dose as an active placebo control | Prompt and long-lasting benefits (up to six months or longer). The therapy’s effectiveness is largely attributed to mystical experiences characterized by a sense of unity and profound emotional insights. |
| New York University Trial | 29 patients were randomly assigned to receive either psilocybin or the active placebo niacin | The findings mirrored those of the Johns Hopkins study. Participants who were given psilocybin reported psychological relief and an improved perspective on life and death. |
| BMC Palliative Care | Nineteen participants (comprising 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist) were interviewed. The goal of the study was to understand how palliative care professionals perceive existential distress and how they view psychedelic therapy as a treatment option. | According to palliative care practitioners, psychedelic-assisted therapy (PAT) shows potential in mitigating existential distress. |
Experiences of Patients
Scientific studies aren’t the only source of evidence backing the effectiveness of psilocybin. Several patient narratives underscore its ability to enhance mental wellbeing and overall life quality.
Yokoi’s Journey
Mio Yokoi, suffering from terminal stage 4 pancreatic cancer, recounts an enlightening experience during her assisted therapy. She imagines being on a raft, encompassed by nature, and accompanied by fanciful creatures. This vision instills in her a deep acknowledgment of the universe’s interconnectedness and support, bringing her immense peace and affirmation.
Despite receiving traditional mental health support, Yokoi continued to experience intense anxiety and distress after her diagnosis. Psilocybin therapy helped her regain a connection with her body and offered a palpable sense of love and support. This has greatly enhanced her emotional and mental health.
Chrissy’s Story
Chrissy, a woman in her 50s, had stage 4 breast cancer that had spread to her lungs. She held a full-time position as an administrative supervisor in healthcare when the study was conducted and identified herself as an atheist. Generalized Anxiety Disorder was diagnosed during her screening.
Chrissy reported substantial reductions in her levels of anxiety, depression, fear of death, hopelessness, and demoralization. When questioned about any changes in her religious or spiritual beliefs since her therapy session, she responded that the experiences had injected meaning and reality into her beliefs.
Brenda’s Experience
Brenda, a woman in her 60s, had been diagnosed with stage I colon cancer. She was identified as having never used hallucinogens during screening and met the criteria for Chronic Adjustment Disorder accompanied by Anxiety.
During her therapy sessions, Brenda had the experience of dying twice. She emerged from the sessions unafraid of death, viewing it as a beautiful part of life’s cycle. She acknowledged the study as the trigger for her healing journey from childhood trauma. Her data mirrored this dramatic transformation.
Reduced anxiety and fear of death, paired with heightened spirituality, have been noted.
Selection of Magic Mushroom Products in Canada
Currently, the availability of psilocybin capsules and other products intended for managing existential distress or other mental health issues may be restricted. However, dependable online dispensaries are a good source for these products when required.
| Characteristic | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Originates from Brazil and some neighboring South American countries. | Found in Cambodia, around the Angkor Wat Temple. | Related to Penis Envy mushrooms, which gained popularity in the 1970s. |
| Potency | Of moderate potency; suitable for novices. | Also of moderate potency; ideal for beginners. | Highly potent; recommended for those with intermediate to advanced experience. |
| Effects | Induces a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Provokes an energizing and long-lasting high, minor visual alterations, increased creativity, euphoria, a smooth physical high, fractal images, and feelings of happiness. | Creates deep shamanic experiences, vision quests, intense mystical experiences, heightened creativity, focus, social awareness, and mood enhancement. |
Alleviate End-of-life Discomfort with Psilocybin Products
Existential or end-of-life distress can place a significant strain on many patients as their lives draw to a close. Traditional treatments for this distress can sometimes fall short, leading to a growth in Canadian support for easier access to magic mushrooms within public healthcare. This rising public interest could encourage regulatory bodies to consider magic mushrooms as a viable treatment alternative. Source your psychedelics and shroom delivery from Sero Canada.
Commonly Asked Questions
What can patients anticipate when undergoing Psilocybin-Assisted Therapy?
Patient experiences with Psychedelic-assisted therapy (PAT) can vary greatly, and careful preparation and adherence to specific steps are important for ensuring a positive outcome. Patients need to undergo thorough screening and mental preparedness before consuming the substance.
- Preparation before the Session: Patients undergo a comprehensive evaluation. The therapist discusses the patient’s objectives and anticipations to establish intentions for the session. The therapist explains to the patient the impact of the process and what they should anticipate during the session.
- The Session: Patients are administered a controlled dose of the substance during the session, which takes place in a comfortable, distraction-free setting to encourage relaxation and introspection. Throughout this, the therapist provides continuous support and guidance.
- Post-Session Integration Therapy: This therapy aids the patient in understanding and processing their experiences. Subsequent sessions offer continuous support and counselling to strengthen the insights and transformations achieved during therapy.
What impact does psilocybin have on the brains of distressed patients?
It interacts with the brain by binding to serotonin receptors, especially the 5-HT2A receptor. This interaction can lead to changes in perception, mood, and cognition, resulting in significant shifts in consciousness, emotional revelations, and fresh perspectives.
Is psilocybin therapy accessible to everyone?
Psilocybin therapy isn’t suitable for all individuals. Patients with certain mental health issues or existential distress undergo thorough screening to exclude those with a history of psychosis.
Related Articles:
